Larissa Brunaldi (@larissabrunaldi) header
Larissa Brunaldi (@larissabrunaldi) profile picture

CAR T Cell Therapy Research Trainee @mayoclinic - Hematology, BMT and Cell Therapy. Views are my own

Ribeirão Preto, Brasil
Joined November 2018
Photo by Larissa Brunaldi (@larissabrunaldi)
Larissa Brunaldi retweeted
Truly transformative data #ASH25 Very exciting time for #mmsm patients! Understanding sequence among novel immunotherapies is more important than ever! @MayoCancerCare @IMFmyeloma #IMWG Immunotherapy Committee @SurbhiSidanaMD @DrKrinaPatel Doris Hansen @MoffittNews @HiraSMian
OK here it is. Finally. My #ASH25 algorithm for Relapsed Myeloma: First Relapse. Discussed with @YiLinMDPhD @myelomaMD Give comments. I’m willing to adjust it based on your insights.
4
18
3,190
Practical guidelines and recommendations for infection prophylaxis with CAR T and bispecific antibodies in #MultipleMyeloma from the COMMIT Consortium onlinelibrary.wiley.com/doi/… @MeeraMohanMD @End_myeloma @rajshekharucms @SusanBal9 @nsc_natalie @BerdejaJesus #mmsm
33
72
6,172
Ivan Borrello reviewing T cell exhaustion and CART in MM #ASCO23RF #mmsm ⁦@IvanBorrello⁩
1
7
21
2,391
Larissa Brunaldi retweeted
Check out abstract 1533 @ASCO #ASCO2023 for Teclistamab infusions in the outpatient setting with use of remote patient monitoring. @larissabrunaldi @YiLinMDPhD @jonaspaludo 👉23pt =155 infusions = 98% administered outpt (80% NEVER ADMITTED) ##HCSM #MedEd #mmsm #DigitalHealth
2
5
1,251
#ASCO23 abstract1533 suggests that hospital-based outpatient setting is feasible and safe for administering and monitoring CAR-T #TCellRx and bispecific TCE therapies. #mmsm #lymsm @Radhika_Bansl @YiLinMDPhD @jonaspaludo mayocl.in/43mnCDn
5
1
18
6,768
Check out abstract 1533 @ASCO #ASCO2023 for Teclistamab infusions in the outpatient setting with use of remote patient monitoring. @larissabrunaldi @YiLinMDPhD @jonaspaludo 👉23pt =155 infusions = 98% administered outpt (80% NEVER ADMITTED) ##HCSM #MedEd #mmsm #DigitalHealth
#ASCO23 abstract1533 suggests that hospital-based outpatient setting is feasible and safe for administering and monitoring CAR-T #TCellRx and bispecific TCE therapies. #mmsm #lymsm @Radhika_Bansl @YiLinMDPhD @jonaspaludo mayocl.in/43mnCDn
8
1
20
4,452
Larissa Brunaldi retweeted
Replying to @larissabrunaldi
@larissabrunaldi presented @MayoCancerCare experience with outpatient management of #CART & #BsAb Teclistamab: 23 patient and 155 injections given. #ASCO23
1
2
1
8
1,528
Larissa Brunaldi retweeted
WoMMen in #mmsm
3
8
739
Larissa Brunaldi retweeted
Check out poster by @larissabrunaldi, visiting researcher from Brazil, presents data from @MayoCancerCare study of 161 myeloma pts treated with #CART that bone marrow and PET MRD negativity is prognostic for early relapse vs prolonged PFS #mmsm #ASCO23
1
7
19
1,929
Larissa Brunaldi retweeted
Replying to @Rfonsi1
Thanks for the shout-out, Dr. Fonseca! Would be great if ASCO and other meetings with large international participation would allow interpreters for more engaged Q&A. It’s another aspect of DEI for our scientific community.
3
8
3
88
6,319
I heard yesterday that a presenter from China at #ASCO23 was struggling to answer questions due to language barriers, after she did an excellent presentation. Dr. @YiLinMDPhD stepped in and said: “I’m here to translate.” Well done!
13
34
9
337
61,977
Larissa Brunaldi retweeted
For #ASCO23 How I treat myeloma: a few slides.
5
69
2
212
42,935
My theme, “Partnering w patients, the cornerstone of clinical care and research” builds on my career of more than 30 yrs & resonates w many of the challenges in oncology today. The theme promotes the preeminence of the relationship btwn pts & the oncology clinician #ASCO23
5
32
8
141
23,967
👉BM MRD at month one post #CART is prognostic regardless bone marrow cellularity for pts with MM rdcu.be/c9joS #mmsm @BloodCancerJnl @Radhika_Bansl @YiLinMDPhD @Taxkourel @Rfonsi1 @myelomaMD
1
3
6
903
🤔@Radhika_Bansl What about extra medullary disease? Is there a role from PET-CT in this scenario? #ASCO2023
2
111
Larissa Brunaldi retweeted
mSMART guidelines for management of CAR-T associated cytokine release syndrome, neurotoxicity, cytopenias has just been posted. #myeloma #MedTwitter @YiLinMDPhD @myelomaMD @MorieGertz @MayoMyeloma msmart.org
6
16
3
57
14,960
Larissa Brunaldi retweeted
Late onset neurologic symptoms and prolonged, severe cytopenia can be particularly difficult to manage. Patients have returned home by then, care require close collaboration between #CART center and home myeloma team. #mmsm
mSMART guidelines for management of CAR-T associated cytokine release syndrome, neurotoxicity, cytopenias has just been posted. #myeloma #MedTwitter @YiLinMDPhD @myelomaMD @MorieGertz @MayoMyeloma msmart.org
1
5
23
3,888
Larissa Brunaldi retweeted
For drug approval and for clinical trial eligibility, specifying refractoriness to specific drugs/drug classes is sufficient & better than mandating number of specific lines of therapy a patient must have previously received. #MedTwitter @BloodCancerJnl nature.com/articles/s41408-0…
1
20
38
8,122